VCYT
Veracyte, Inc. NASDAQ Listed Oct 30, 2013$40.76
Mkt Cap $3.3B
52w Low $22.61
64.6% of range
52w High $50.71
50d MA $33.41
200d MA $35.71
P/E (TTM)
39.4x
EV/EBITDA
33.3x
P/B
2.0x
Debt/Equity
0.0x
ROE
5.1%
P/FCF
26.1x
RSI (14)
—
ATR (14)
—
Beta
1.96
50d MA
$33.41
200d MA
$35.71
Avg Volume
905.1K
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
6000 Shoreline Court · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.34 | 0.36 | +5.9% | 32.97 | +18.3% | +24.9% | +23.6% | — | — | — | — |
| Feb 25, 2026 | AMC | 0.41 | 0.53 | +29.8% | 35.72 | +7.8% | +8.5% | +2.4% | +0.8% | -1.8% | +1.5% | — |
| Nov 4, 2025 | AMC | 0.32 | 0.51 | +59.4% | 36.12 | +10.7% | +27.5% | +15.4% | +15.4% | +17.2% | +18.1% | — |
| Aug 6, 2025 | AMC | 0.31 | 0.44 | +41.9% | 23.97 | +8.5% | +15.5% | +14.2% | +16.8% | +20.0% | +28.0% | — |
| May 7, 2025 | AMC | 0.20 | 0.31 | +55.0% | 30.84 | -2.1% | +1.2% | -3.7% | -0.3% | -5.0% | -7.6% | — |
| Feb 24, 2025 | AMC | 0.10 | 0.36 | +260.0% | 39.36 | -8.3% | -15.0% | -9.7% | -14.0% | -11.7% | -14.7% | — |
| Nov 6, 2024 | AMC | 0.03 | 0.19 | +603.7% | 36.59 | +8.5% | +2.0% | -0.3% | +6.3% | +4.5% | +8.0% | — |
| Aug 6, 2024 | AMC | 0.05 | 0.30 | +530.7% | 21.82 | +20.1% | +24.0% | +37.4% | +34.1% | +37.1% | +49.2% | — |
| May 7, 2024 | AMC | -0.19 | -0.02 | +89.5% | 21.03 | +3.1% | -4.3% | -1.9% | +1.6% | +7.0% | +9.5% | — |
| Feb 22, 2024 | AMC | -0.07 | -0.04 | +42.9% | 24.34 | -2.2% | -8.9% | -3.2% | -3.0% | -2.3% | -3.2% | — |
| Nov 7, 2023 | AMC | -0.16 | -0.03 | +81.2% | 24.01 | +3.9% | -3.6% | -10.6% | -7.5% | -4.4% | +5.2% | — |
| Aug 8, 2023 | AMC | -0.16 | -0.12 | +25.0% | 25.00 | +5.9% | +7.0% | +1.8% | +0.6% | +1.4% | +0.1% | — |
| May 4, 2023 | AMC | -0.14 | -0.11 | +21.4% | 22.26 | +3.2% | +4.6% | +1.7% | +3.2% | +6.2% | +5.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Canaccord Genuity | Maintains | Hold → Hold | — | $33.80 | $33.35 | -1.3% | -1.0% | -0.9% | -0.3% | -1.9% | +1.6% |
| Apr 1 | Needham | Maintains | Buy → Buy | — | $32.21 | $32.31 | +0.3% | +0.6% | +0.1% | +0.3% | -0.2% | +1.4% |
| Mar 30 | Guggenheim | Maintains | Buy → Buy | — | $30.01 | $30.20 | +0.6% | +1.4% | +7.3% | +8.0% | +7.5% | +7.7% |
| Mar 6 | Morgan Stanley | Maintains | Underweight → Underweight | — | $34.68 | $33.34 | -3.9% | -2.4% | -3.8% | -5.5% | -6.4% | -10.8% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $35.72 | $38.51 | +7.8% | +8.5% | +2.4% | +0.8% | -1.8% | +1.5% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $42.39 | $42.41 | +0.0% | +2.9% | +7.7% | +6.4% | +2.8% | -0.8% |
| Dec 2 | Morgan Stanley | Maintains | Underweight → Underweight | — | $46.39 | $46.25 | -0.3% | -0.5% | +2.9% | +2.2% | -3.8% | -4.4% |
| Nov 11 | Morgan Stanley | Maintains | Underweight → Underweight | — | $42.35 | $42.44 | +0.2% | +0.7% | -0.1% | -5.9% | -7.1% | -7.2% |
| Nov 5 | UBS | Maintains | Buy → Buy | — | $36.12 | $40.00 | +10.7% | +27.5% | +15.4% | +15.4% | +17.2% | +18.1% |
| Nov 5 | Canaccord Genuity | Maintains | Hold → Hold | — | $36.12 | $40.00 | +10.7% | +27.5% | +15.4% | +15.4% | +17.2% | +18.1% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $36.12 | $40.00 | +10.7% | +27.5% | +15.4% | +15.4% | +17.2% | +18.1% |
| Nov 5 | Guggenheim | Maintains | Buy → Buy | — | $36.12 | $40.00 | +10.7% | +27.5% | +15.4% | +15.4% | +17.2% | +18.1% |
| May 8 | Needham | Maintains | Buy → Buy | — | $30.84 | $30.19 | -2.1% | +1.2% | -3.7% | -0.3% | -5.0% | -7.6% |
| May 8 | UBS | Maintains | Buy → Buy | — | $30.84 | $30.19 | -2.1% | +1.2% | -3.7% | -0.3% | -5.0% | -7.6% |
| Apr 9 | Guggenheim | Maintains | Buy → Buy | — | $28.88 | $27.22 | -5.7% | +13.0% | +4.7% | +10.1% | +11.3% | +10.0% |
| Mar 26 | Stephens & Co. | Maintains | Overweight → Overweight | — | $33.69 | $33.60 | -0.3% | -7.8% | -7.7% | -10.6% | -12.0% | -12.3% |
| Feb 25 | UBS | Maintains | Buy → Buy | — | $39.36 | $36.10 | -8.3% | -15.0% | -9.7% | -14.0% | -11.7% | -14.7% |
| Feb 25 | Guggenheim | Maintains | Buy → Buy | — | $39.36 | $36.10 | -8.3% | -15.0% | -9.7% | -14.0% | -11.7% | -14.7% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $39.36 | $36.10 | -8.3% | -15.0% | -9.7% | -14.0% | -11.7% | -14.7% |
| Jan 29 | Needham | Maintains | Buy → Buy | — | $43.67 | $44.30 | +1.4% | +1.8% | +5.7% | +4.1% | +3.2% | +0.2% |
| Dec 5 | Goldman Sachs | Downgrade | Buy → Neutral | — | $44.09 | $42.00 | -4.7% | -2.8% | +0.1% | -3.0% | -2.5% | -1.3% |
| Nov 18 | Morgan Stanley | Maintains | Underweight → Underweight | — | $35.94 | $36.05 | +0.3% | +2.1% | +8.9% | +9.1% | +8.3% | +10.2% |
| Nov 8 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $37.34 | $37.15 | -0.5% | -2.3% | +4.2% | +2.4% | +5.9% | -0.8% |
| Nov 7 | UBS | Maintains | Buy → Buy | — | $36.59 | $39.70 | +8.5% | +2.0% | -0.3% | +6.3% | +4.5% | +8.0% |
| Nov 7 | Goldman Sachs | Maintains | Buy → Buy | — | $36.59 | $39.70 | +8.5% | +2.0% | -0.3% | +6.3% | +4.5% | +8.0% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $36.59 | $39.70 | +8.5% | +2.0% | -0.3% | +6.3% | +4.5% | +8.0% |
| Oct 17 | Leerink Partners | Maintains | Outperform → Outperform | — | $34.72 | $34.78 | +0.2% | -1.2% | -0.8% | -4.6% | -6.1% | -6.5% |
| Aug 28 | Needham | Maintains | Buy → Buy | — | $32.00 | $32.14 | +0.4% | -1.2% | -0.2% | -1.4% | -5.3% | -7.7% |
| Aug 12 | Morgan Stanley | Maintains | Underweight → Underweight | — | $29.27 | $29.84 | +1.9% | +2.2% | +11.2% | +6.6% | +11.6% | +12.2% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $21.82 | $26.20 | +20.1% | +24.0% | +37.4% | +34.1% | +37.1% | +49.2% |
| May 8 | Needham | Maintains | Buy → Buy | — | $21.03 | $21.68 | +3.1% | -4.3% | -1.9% | +1.6% | +7.0% | +9.5% |
| Apr 15 | Goldman Sachs | Maintains | Buy → Buy | — | $20.23 | $20.18 | -0.2% | -4.3% | -6.5% | -6.8% | -5.1% | -3.9% |
| Feb 26 | Morgan Stanley | Maintains | Underweight → Underweight | — | $22.18 | $21.88 | -1.4% | +6.2% | +6.5% | +7.2% | +6.2% | +8.2% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $24.34 | $23.80 | -2.2% | -8.9% | -3.2% | -3.0% | -2.3% | -3.2% |
| Nov 10 | Morgan Stanley | Maintains | Underweight → Underweight | — | $21.47 | $21.45 | -0.1% | +3.4% | +6.9% | +17.6% | +16.5% | +15.1% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $24.01 | $24.94 | +3.9% | -3.6% | -10.6% | -7.5% | -4.4% | +5.2% |
| Oct 23 | Goldman Sachs | Maintains | Buy → Buy | — | $20.93 | $20.63 | -1.4% | -0.8% | +2.5% | -4.7% | -2.4% | -5.8% |
| Oct 20 | Goldman Sachs | Maintains | Buy → Buy | — | $20.79 | $20.80 | +0.0% | +0.7% | -0.1% | +3.2% | -4.0% | -1.8% |
| Oct 10 | Stephens & Co. | Maintains | Overweight → Overweight | — | $21.87 | $21.97 | +0.5% | +3.2% | +2.1% | -3.9% | -2.7% | -2.7% |
| Aug 9 | Morgan Stanley | Maintains | Underweight → Underweight | — | $25.00 | $26.48 | +5.9% | +7.0% | +1.8% | +0.6% | +1.4% | +0.1% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $25.00 | $26.48 | +5.9% | +7.0% | +1.8% | +0.6% | +1.4% | +0.1% |
| May 8 | Stephens & Co. | Maintains | Overweight → Overweight | — | $23.28 | $23.19 | -0.4% | -2.8% | -1.3% | +1.6% | +1.3% | +1.0% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $23.90 | $26.30 | +10.0% | +0.1% | -0.5% | +1.3% | +3.0% | -0.8% |
| Jan 18 | Raymond James | Downgrade | Outperform → Market Perform | — | $26.69 | $25.88 | -3.0% | -2.9% | -10.3% | -6.7% | -1.4% | -3.1% |
| Jan 5 | Scotiabank | Maintains | Sector Outperform → Outperform | — | $23.77 | $23.92 | +0.6% | -2.8% | -5.8% | -3.0% | +0.9% | +6.1% |
| Nov 4 | Raymond James | Maintains | Outperform → Outperform | — | $24.23 | $24.50 | +1.1% | +0.6% | +2.1% | +3.0% | -4.7% | +15.4% |
| Nov 4 | Morgan Stanley | Maintains | Underweight → Underweight | — | $24.23 | $24.50 | +1.1% | +0.6% | +2.1% | +3.0% | -4.7% | +15.4% |
| Nov 3 | SVB Leerink | Maintains | Outperform → Outperform | — | $19.50 | $22.98 | +17.8% | +24.3% | +25.0% | +26.8% | +28.0% | +18.4% |
| Nov 3 | Needham | Maintains | Buy → Buy | — | $19.50 | $22.98 | +17.8% | +24.3% | +25.0% | +26.8% | +28.0% | +18.4% |
| Aug 4 | Raymond James | Maintains | Outperform → Outperform | — | $25.05 | $25.59 | +2.2% | +10.4% | +11.4% | +7.1% | -3.7% | +3.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | McGuire AnnieOff | SVP, General Counsel | Sell | 5,102 | $38.05 | $194K | 148,810 | — | — |
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Leadership transitions with equity incentives can signal confidence in succession planning, but investors should monitor whether new executives meet performance targets to ensure shareholder value isn't diluted through excessive equity grants.
Mar 16
8-K
Veracyte, Inc. -- 8-K Filing
Veracyte's fourth quarter testing revenue grew 21% to $135.8 million, demonstrating strong operational momentum in its diagnostic testing business.
Feb 25
Data updated apr 27, 2026 7:27am
· Source: massive.com